Acquisitions (Narrative) (Details)	3 Months Ended		9 Months Ended			0 Months Ended			3 Months Ended			9 Months Ended				0 Months Ended		0 Months Ended			0 Months Ended				0 Months Ended		0 Months Ended		0 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)	Dec. 31, 2013 USD ($)	Feb. 28, 2014 Endo Health Solutions Inc. [Member]	Feb. 28, 2014 Paladin Labs Inc. [Member] USD ($)	Feb. 28, 2014 Paladin Labs Inc. [Member] CAD	Sep. 30, 2014 Paladin Labs Inc. [Member] USD ($)	Mar. 31, 2014 Paladin Labs Inc. [Member] USD ($)	Sep. 30, 2013 Paladin Labs Inc. [Member] USD ($)	Sep. 30, 2014 Paladin Labs Inc. [Member] USD ($)	Sep. 30, 2013 Paladin Labs Inc. [Member] USD ($)	Sep. 30, 2014 Paladin Labs Inc. [Member] Minimum [Member]	Sep. 30, 2014 Paladin Labs Inc. [Member] Maximum [Member]	Feb. 03, 2014 Boca Pharmacal, LLC [Member] USD ($)	Feb. 03, 2014 Boca Pharmacal, LLC [Member] USD ($)	Feb. 03, 2014 Boca Pharmacal, LLC [Member] Developed technology [Member]	Feb. 03, 2014 Boca Pharmacal, LLC [Member] Developed technology [Member] USD ($)	Feb. 03, 2014 Boca Pharmacal, LLC [Member] In process research & development [Member] USD ($)	Apr. 24, 2014 Sumavel DosePro [Member] USD ($)	Jun. 30, 2014 Sumavel DosePro [Member] Minimum [Member] USD ($)	Jun. 30, 2014 Sumavel DosePro [Member] Maximum [Member] USD ($)	Apr. 24, 2014 Sumavel DosePro [Member] Zogenix, Inc [Member] USD ($)	Jul. 24, 2014 Grupo Farmacéutico Somar [Member] USD ($)	Jul. 24, 2014 Grupo Farmacéutico Somar [Member] USD ($)	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] USD ($)	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] USD ($)	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] Developed technology [Member]	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] Developed technology [Member] USD ($)	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] In process research & development [Member] USD ($)	Aug. 06, 2014 DAVA Pharmaceuticals, Inc [Member] Maximum [Member] USD ($)
Business Acquisition [Line Items]
Number of New Endo shares Issued per share of Paladin Labs (shares)							1.6331	1.6331
Number of New Endo shares issued of Paladin Labs (shares)							35,500,000.0	35,500,000.0
Cash payment issued per share of acquired entity (cd per share)							$ 1.09	1.16
Aggregate consideration transferred							$ 2,866,926,000																				$ 595,000,000
Number of New Endo shares issued per share of Endo (shares)						1
Equity interest in combined entity (percent)						79.00%	21.00%	21.00%
Proceeds from sale of intangible assets	4,200,000
Discount rate range (percent)														9.50%	15.00%
Transaction costs										33,400,000
Interest expense									(1,000,000)		2,100,000	(1,000,000)	5,700,000
Amortization of intangible assets	70,806,000	44,987,000	194,273,000	143,326,000					0		4,500,000	3,600,000	14,200,000
Accrued excise taxes	54,300,000		54,300,000
Payments to acquire business																232,700,000					89,700,000				270,100,000		590,200,000
Net identifiable assets acquired							807,218,000										221,800,000				90,400,000					160,600,000		368,345,000
Goodwill	3,804,959,000		3,804,959,000		1,372,832,000		2,100,308,000										10,800,000				3,000,000					109,500,000		226,683,000
Identifiable intangible assets																	165,900,000		105,200,000	60,700,000	84,400,000					114,700,000
Estimated useful life																		14 years			13 years				14 years				14 years
Estimated fair value																					93,400,000
Contingent consideration																					3,700,000	0	20,000,000.0					4,800,000				25,000,000.0
Loan for working capital needs																								7,000,000
Revenue reported by acquired entity for last annual period																									100,000,000
Intangible assets							650,248,000																			128,000,000		439,623,000		360,700,000	78,900,000
Indefinite intangible assets																										$ 13,300,000